Approved GLP-1 drugs treat conditions beyond body mass. At Longevity Benchmark, we trace every therapeutic claim back to the package insert. Every clinical benefit attaches to a defined diagnosis. Marketing claims routinely drop the population attached to each indication. Two major indications expand this category into new clinical territory. Regulatory authorities approve these medications for kidney preservation and airway stability only in patients with qualifying comorbid conditions. Other outcomes for cardiovascular risk and steatohepatitis carry separate evidentiary standards.
The Verdict
The Two Non-Weight Endpoints This Site Has Not Covered
Two approved indications reach beyond weight: chronic kidney disease and obstructive sleep apnea (OSA).
Clinical trials evaluated these endpoints against objective medical criteria. The results produced federal label updates for specific patient groups. Cardiovascular risk, MASH and brain research each have a dedicated page on this site, linked below. The kidney and sleep apnea indications do not.
Federal approval requires meeting precise diagnostic thresholds. A prescription for renal risk reduction requires documented kidney impairment alongside diabetes. Treatment for sleep apnea requires confirmed airway obstruction with concurrent obesity. Neither outcome applies to general wellness populations. The table below outlines how federal labels define each therapeutic endpoint across the drug class.
| Endpoint | What the Label Actually Says | Who the Indication Covers | Where We Cover It |
|---|---|---|---|
| Chronic Kidney Disease | To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease | Adults with type 2 diabetes mellitus and chronic kidney disease | Covered in full below; see our guide to eGFR biomarkers |
| Obstructive Sleep Apnea | To treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity | Adults with obesity and moderate to severe OSA | Covered in full below; see our home sleep apnea test guide |
| Cardiovascular Disease | A labelled indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight | Adults with established cardiovascular disease and either obesity or overweight | Read our Ozempic vs Wegovy comparison |
| Metabolic Dysfunction-Associated Steatohepatitis (MASH) | For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis in adults | Adults with noncirrhotic MASH and moderate to advanced liver fibrosis under accelerated approval | Read our analyses on low-dose GLP-1 evidence and the oral Wegovy tablet |
| Brain and Neurobehavioral Function | No labelled indication | No labelled population | Read our dedicated guide to GLP-1 and the brain |
The Kidney Indication and GLP-1 Benefits Beyond Weight Loss
Federal drug labeling indicates semaglutide to slow renal decline and decrease mortality in patients with combined metabolic and kidney disorders.
According to the official prescribing information on DailyMed, the Ozempic injection label includes a dedicated renal indication. The statutory text authorizes the medication "to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease." This language ties therapeutic efficacy directly to dual baseline pathologies.
The population is the whole of this indication. The indication does not cover patients with isolated obesity or individuals with normal renal markers. A patient must carry clinical diagnoses of both type 2 diabetes and chronic kidney disease. Furthermore, the label conditions this renal risk reduction on a specific maintenance dosage level rather than initial titration strengths. The product also carries indications as an adjunct to diet and exercise for glycemic control and for reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
The Cardiovascular Death Component Inside Kidney Outcomes
Composite renal endpoints integrate cardiovascular death because vascular disease and renal filtration failure progress along connected biological systems.
The approved kidney label targets three related events. The first component is sustained estimated glomerular filtration rate (eGFR) decline, which reflects a permanent loss in how effectively the kidneys filter waste. Readers can track this benchmark using a specialized kidney function test. The second component is end-stage kidney disease, defined as complete organ failure requiring ongoing dialysis or a kidney transplant.
Cardiovascular death constitutes the third component. It sits inside a kidney indication because the two risks travel together.
The Obstructive Sleep Apnea Indication and Dual Agonism
The Food and Drug Administration (FDA) approved tirzepatide as the first prescription pharmaceutical treatment for moderate to severe obstructive sleep apnea in adults with obesity.
The package insert for Zepbound on DailyMed documents this respiratory indication. The label specifies use in combination with a reduced-calorie diet and increased physical activity. Qualifying patients must exhibit moderate to severe airway collapse alongside clinical obesity. The statutory approval excludes mild sleep apnea and does not indicate the drug for simple snoring.
Tirzepatide differs chemically from single-target medications. The prescribing information defines it as a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. This combined molecular mechanism distinguishes it from pure GLP-1 medications. The label also links the sleep apnea indication specifically to the higher maintenance dosages. Additionally, the label limitations of use explicitly advise against combining tirzepatide with other tirzepatide products or any GLP-1 receptor agonist.
Cardiovascular, Liver, and Brain Endpoints Covered Elsewhere
Outside of kidney and sleep indications, regulatory authorities have approved semaglutide formulations for cardiovascular risk reduction and steatohepatitis under separate standards.
Under its approved label on the FDA drug database, Wegovy is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The agency confirmed this as the first weight-loss medication approved to prevent serious cardiac events in that demographic on its FDA cardiovascular approval announcement. We review those clinical trials and cardiovascular outcomes in our Ozempic vs Wegovy comparison.
For liver health, Wegovy holds an accelerated approval indication for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults. Accelerated approval differs from traditional approval because continued marketing remains contingent upon verifying clinical benefit in confirmatory trials. We analyze the histological evidence and oral formulations in our reviews of low-dose GLP-1 evidence and the oral Wegovy tablet. Finally, we cover brain and behaviour in our dedicated guide to GLP-1 and the brain.
Boxed Warnings, Gallbladder Risks, and Removed Precautions
Therapeutic indications on metabolic drug labels exist alongside statutory warnings detailing severe endocrine, pancreatic, and digestive safety risks.
The Wegovy prescribing information carries a prominent boxed warning regarding thyroid C-cell tumors observed in animal studies. In rodent experiments, semaglutide caused thyroid C-cell tumors at clinically relevant exposures. The relevance of these rodent findings to humans remains undetermined. Consequently, the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Additional warnings detail risks of acute pancreatitis and acute gallbladder disease. Patients also face an increased risk of severe hypoglycemia when combining these agents with insulin or insulin secretagogues. Safety surveillance continuously modifies these documents. The Wegovy label's Indications and Usage section changed in August 2025 and December 2025, followed by the formal removal of a warning regarding suicidal behavior and ideation in February 2026. Readers can evaluate these adverse patterns in our guide on semaglutide side effects.
Assessing GLP-1 Benefits Beyond Weight Loss in Clinical Practice
Interpreting therapeutic claims requires evaluating whether an individual patient matches the specific populations evaluated in pivotal regulatory trials.
Every non-weight indication on a package insert applies to a defined medical group. Patients without diabetes and nephropathy cannot claim the renal risk reduction benefit. Similarly, individuals without obesity and confirmed sleep apnea do not qualify for the airway maintenance indication. Using these medications for off-label longevity goals without qualifying diagnoses departs entirely from established regulatory evidence.
What would change our answer is the publication of positive randomized trial data that expands indications to non-diabetic kidney patients or non-obese sleep apnea cohorts. Until regulators review such data, therapeutic benefits remain limited to labeled populations. Whether a given person falls inside one of these labelled populations is a clinical question, not a marketing one. Our comparison of peptide therapy vs GLP-1 medications covers how the two categories differ.
Frequently Asked Questions
What does a GLP-1 do besides weight loss?
Approved GLP-1 and dual-agonist medications treat chronic kidney disease and obstructive sleep apnea alongside their established metabolic uses. In adults with type 2 diabetes and chronic kidney disease, semaglutide holds approval to reduce sustained eGFR decline, end-stage kidney disease, and cardiovascular death. For respiratory health, the dual GIP and GLP-1 agonist tirzepatide is indicated to treat moderate to severe obstructive sleep apnea in adults with obesity. Additionally, semaglutide carries approvals to reduce major adverse cardiovascular events in established cardiovascular disease with obesity or overweight, and holds accelerated approval for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis.
What are the benefits of GLP-1 beyond weight loss?
The primary clinical benefits include renal filtration protection, respiratory stabilization during sleep, cardiovascular risk reduction, and hepatic fibrosis improvement. Each therapeutic benefit requires a specific diagnostic baseline. Renal indications require diagnosed chronic kidney disease combined with type 2 diabetes. Sleep apnea indications require confirmed moderate to severe airway collapse combined with clinical obesity. Cardiovascular risk reduction applies to patients with established cardiovascular disease. Hepatic indications under accelerated approval cover noncirrhotic MASH with moderate to advanced liver fibrosis in adults. These outcomes represent statutory, disease-specific indications rather than non-specific wellness enhancements for healthy individuals.
Do GLP-1 drugs protect your kidneys?
Semaglutide holds an approved indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Estimated glomerular filtration rate (eGFR) measures how effectively kidneys remove metabolic waste from the blood. End-stage kidney disease represents irreversible failure requiring chronic dialysis or kidney transplantation. The package insert attaches this protective outcome to a specific maintenance dosage level. However, this indication does not extend to patients who have normal kidney function or who manage weight without a type 2 diabetes diagnosis.
Is a GLP-1 approved for sleep apnoea?
The Food and Drug Administration approved tirzepatide to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, alongside reduced-calorie diet and exercise. Tirzepatide functions as a dual GIP receptor and GLP-1 receptor agonist rather than a pure GLP-1 agent. The approved prescribing information restricts this indication to moderate or severe clinical airway obstruction in individuals with obesity. It is not approved for mild sleep apnea or uncomplicated snoring. Furthermore, the label conditions the sleep apnea indication on reaching higher maintenance dosage tiers.
Does a GLP-1 help your heart?
Semaglutide is approved to reduce the risk of major adverse cardiovascular events, in adults with established cardiovascular disease and either obesity or overweight. The indication applies to both injectable and oral tablet formulations. We analyze these clinical trials, composite endpoints, and dosing structures in our detailed Ozempic vs Wegovy comparison.
Is a GLP-1 approved for fatty liver disease?
Semaglutide holds accelerated approval to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults. Accelerated approval is granted based on improvements in liver histology, but continued regulatory approval remains contingent upon verifying clinical outcomes in confirmatory trials. We review the histological endpoints in our guides on low-dose GLP-1 evidence and the oral Wegovy tablet.
Do you have to have diabetes to get the kidney benefit?
Yes. The statutory kidney indication approved on the official Ozempic label strictly covers adults with type 2 diabetes mellitus and chronic kidney disease. Nothing in the regulatory documentation extends this renal indication to individuals without diabetes or to patients with normal baseline kidney filtration. Individuals with isolated obesity or non-diabetic metabolic concerns do not qualify under the approved prescribing parameters.
Does a GLP-1 do anything for the brain?
This site covers brain and behaviour research separately in our dedicated guide to GLP-1 and the brain.
Related
- Ozempic vs Wegovy comparison and cardiovascular evidence
- Low-dose GLP-1 clinical trials and liver outcomes
- Wegovy oral tablet indications and prescribing data
- GLP-1 and the brain investigational research
- Semaglutide side effects and boxed warnings
- Home sleep apnea test options and diagnostic metrics